The World Health Organization (WHO) documented 10.6 million new tuberculosis (TB) cases in 2025, as detailed in its latest Global Tuberculosis Report 2026. Although deaths from TB decreased to 1.1 million, the world has fallen short of its case-reduction goals by significant margins.
Domestic funding for TB programs increased by 14%, reaching $5.6 billion between 2024 and 2025. This rise partially balanced reductions in international support, reflecting a broader trend of national governments taking on more responsibility for essential health services amid shrinking global health budgets.
Since the year 2000, TB treatment has saved an estimated 86 million lives, allowing the world to meet the mortality target set by the WHO’s End TB Strategy—though it arrived five years later than intended. The disease’s incidence rate declined by 14% between 2015 and 2025, a figure still far below the 50% reduction the strategy aimed for.
TB remains the world’s top infectious disease killer. WHO Director-General Dr. Tedros Adhanom Ghebreyesus described the progress as promising but stressed that over 1 million deaths still occur annually despite the availability of effective treatments. He emphasized the need for governments to broaden access to diagnostic tools and speed up the development of new therapies.
Progress across regions shows stark differences. The WHO European Region achieved a 42% reduction in cases since 2015, while the African Region saw a 30% decrease. South-East Asia reduced cases by 18%, but the Americas experienced a 13% rise—the fifth straight annual increase. The Western Pacific showed no overall change in case numbers.
Diagnostic shortfalls continue to hinder response efforts. In 2025, only 8.4 million of the 10.6 million new cases were detected, leaving 2.2 million undiagnosed. Rapid testing coverage among newly diagnosed patients stood at just 59%, well below the 100% goal set for 2027.
Drug-resistant TB poses another major challenge. An estimated 370,000 people developed rifampicin-resistant strains in 2025, but only 42% of them received appropriate treatment. Among those treated, compliance with the WHO’s six-month regimen improved from 18% in 2024 to 42% in 2025.
Research funding remains insufficient to meet demands. Global investment totaled $1.2 billion in 2023, less than a quarter of the $5 billion annual target established for 2027. The WHO has repeatedly highlighted the urgent need for consistent financing to advance new vaccines, diagnostics, and treatments.
The disease’s impact remains heavily concentrated in 30 countries, which accounted for 88% of all new cases in 2025. These disparities stem from uneven healthcare access, infrastructure gaps, and funding inequalities. The WHO has urged stronger political support, expanded prevention initiatives, and better treatment coverage to address these imbalances.
Regional Progress and Funding Gaps in TB Control
The WHO’s report highlights uneven progress in tuberculosis reduction across regions. South-East Asia recorded an 18% reduction, though the Eastern Mediterranean lagged with only a 6.6% decrease. These variations stem from differences in healthcare access, infrastructure, and sustained investment in TB programs.
Leave a Reply